Envestnet Asset Management Inc. Trims Holdings in BioNTech SE (NASDAQ:BNTX)

Envestnet Asset Management Inc. lowered its stake in shares of BioNTech SE (NASDAQ:BNTX) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,477 shares of the company’s stock after selling 476 shares during the period. Envestnet Asset Management Inc.’s holdings in BioNTech were worth $2,333,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BNTX. SG Americas Securities LLC boosted its position in shares of BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after acquiring an additional 33,375 shares during the last quarter. Mirabaud & Cie SA purchased a new position in BioNTech during the fourth quarter worth about $684,000. Bank of New York Mellon Corp boosted its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after purchasing an additional 150 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of BioNTech in the 4th quarter valued at approximately $1,118,000. Finally, Retireful LLC acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $260,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Morgan Stanley lowered their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. HC Wainwright lowered their price target on BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Stock Down 15.4 %

Shares of BioNTech stock opened at $102.02 on Friday. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a 50 day moving average of $101.72 and a 200 day moving average of $110.60. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.48 billion, a P/E ratio of -48.58 and a beta of 1.07.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 EPS. As a group, research analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.